Pharmaceutical

US tariffs likely to disrupt drug development costs and...

While the pharmaceutical industry is currently exempt from US tariffs, there is ...

Myostatin inhibitors target muscle loss prevention to f...

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, b...

AstraZeneca CEO calls for increased European investment...

CEO Soriot said Europe must boost investment in pharma innovation or risk fallin...

Small biotechs shoulder the burdens of an uncertain bio...

Funding troubles and innovation responsibilities are falling more heavily on eme...

UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted ma...

China approves InnoCare Pharma’s BTK inhibitor for lymp...

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-lin...

Granite Bio secures $100m in funding for new antibodies

Granite Bio has secured $100m in funding for its new antibody treatments that ta...

EC grants orphan drug designation to Dyne Therapeutics’...

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for tr...

Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncer...

MSD’s Gardasil sales slide further due to China constra...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufact...

Challenges in filling for alum drug products: What does...

CDMOs are crucial partners in alum-based vaccine production, managing aseptic fi...

Thermo Fisher counters tariffs with $2bn investment int...

Following in the footsteps of several pharma companies, life sciences giant Ther...

Merck KGaA nears $3.5bn deal for SpringWorks

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, ...

FDA free to pursue semaglutide compounders after latest...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector i...

FDA approves Akeso’s monoclonal antibody for nasopharyn...

The FDA has granted approval to Akeso's differentiated programmed cell death pro...

Caribou cuts pipeline and workforce to focus on lead CA...

Caribou is scaling back its operations, halting multiple programmes, and cutting...